Page last updated: 2024-08-21

fluorobenzenes and Hepato-Pulmonary Syndrome

fluorobenzenes has been researched along with Hepato-Pulmonary Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chang, CC; Chuang, CL; Hsieh, HG; Huang, HC; Lee, FY; Lee, SD; Lee, WS; Lin, HC; Wang, SS	1

Other Studies

1 other study(ies) available for fluorobenzenes and Hepato-Pulmonary Syndrome

Article	Year
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung. Clinical science (London, England : 1979), 2015, Volume: 129, Issue:6 Topics: Administration, Oral; Animals; Disease Models, Animal; Down-Regulation; Fluorobenzenes; Hemodynamics; Hepatopulmonary Syndrome; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lung; Male; Neovascularization, Pathologic; Pyrimidines; Rats; Rats, Sprague-Dawley; Reference Values; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2015

Article

Year

Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.

Clinical science (London, England : 1979), 2015, Volume: 129, Issue:6

Topics: Administration, Oral; Animals; Disease Models, Animal; Down-Regulation; Fluorobenzenes; Hemodynamics; Hepatopulmonary Syndrome; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lung; Male; Neovascularization, Pathologic; Pyrimidines; Rats; Rats, Sprague-Dawley; Reference Values; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2015